Clinical Care Team

Patient testimonial videos

Patients share their personal dialysis journeys and how they found success with Velphoro.

Anita W.: Velphoro as a first phosphate-lowering therapy*

Velphoro was prescribed as Anita W.’s first phosphate-lowering therapy. See how it fits into her daily routine and controls her phosphorus levels.

Anita W.: Velphoro as a first phosphate-lowering therapy*

Velphoro was prescribed as Anita W.'s first phosphate-lowering therapy. See how it fits into her daily routine and controls her phosphorus levels.

Elbert & Easter N.: Taking their dialysis journey together*

Elbert and Easter N. switched to Velphoro after transitioning to home dialysis. Hear how Velphoro helped them maintain their phosphorus levels while lowering their pill burden.

Antonio G.: Gaining control of phosphorus levels*

Watch Antonio G. share his personal dialysis journey and how he switched from taking 6 pills per meal with another phosphate binder to only 1 pill per meal with Velphoro.

Robert A.: Taking charge of phosphate management*

Listen to Robert A. recount his experiences with dialysis and Velphoro. By working closely with a dietitian and taking Velphoro with each meal, he was able to keep his phosphorus levels spot-on.

Peer-to-peer videos

Hear how your peers talk to their patients about the unique features of Velphoro, and find out how Velphoro can help with some of the challenges of phosphate management.

The need for potent phosphate binding†

Renal dietitians share their views on why helping patients achieve their phosphorus goals can be challenging, and how Velphoro, the most potent phosphate binder, may help.1

The need for potent phosphate binding†

Renal dietitians share their views on why helping patients achieve their phosphorus goals can be challenging, and how Velphoro, the most potent phosphate binder, may help.1

Educating patients on how to take Velphoro†

Hear renal dietitians talk about why they like the flexibility of Velphoro administration,2 and how they educate their patients about the different ways to take it.

Putting patients in control with Velphoro†

Dialysis and hyperphosphatemia may make some patients feel out of control. Renal dietitians talk, peer-to-peer, about their confidence in Velphoro, and how putting patients in control of how to take it can help.

Setting expectations with Velphoro†

Guidance from renal dietitians focuses on giving patients a better chance of success by setting expectations for Velphoro treatment.

 

Tools specially designed to encourage patient engagement

Download and share the resources below to engage patients and empower them to stay on track with treatment. Need printed copies? Contact your representative or request a visit.

M.O.V.E. Forward With Velphoro patient handout

M.O.V.E. Forward With Velphoro

Focuses on adherence and setting up reminders and goals for long-term success.

GET THE HANDOUT
Patient Certificate

Patient Certificate

Acknowledges a patient’s progress toward their phosphorus goal. 

GET THE CERTIFICATE
Get the certificate in Spanish
Commonly asked questions about Velphoro

Patient Certificates (seasonal themes)

Recognize a patient’s progress toward their phosphorus goals throughout the year.

GET THE CERTIFICATES
Get the certificates in Spanish
Hyperphosphatemia Education Tool

Hyperphosphatemia Education Tool

Show patients how unchecked hyperphosphatemia can impact bones and arteries.

Contact your representative to get this interactive educational tool.

Register for updates

Stay connected with Velphoro and phosphorus management information customized for you and the patients you counsel

REGISTER

 

*The paid testimonial provided is representative of that individual's experience and not all patients may experience these benefits.

†Presenter is a paid speaker and has been compensated for their time.

References: 1. Coyne DW, Larson DS, Delmez JA. Bone disease. In: Daugirdas JT, Blake PG, Ing TS, eds. Handbook of Dialysis. 5th ed, Philadelphia, PA: Wolters Kluwer Health; 2015:665-692. 2. Velphoro® [package insert]. Waltham, MA: Fresenius Medical Care North America; 2024.

INDICATION

Velphoro® (sucroferric oxyhydroxide) is a phosphate binder indicated for the control of serum phosphorus levels in adult and pediatric patients 9 years of age and older with chronic kidney disease on dialysis.

IMPORTANT SAFETY INFORMATION

  • Velphoro chewable tablets must be administered with meals. Velphoro should be chewed or crushed. Do not swallow whole.
  • Patients with peritonitis during peritoneal dialysis, significant gastric or hepatic disorders, following major gastrointestinal (GI) surgery, or with a history of hemochromatosis or other diseases with iron accumulation have not been included in clinical studies with Velphoro. Monitor effect and iron homeostasis in such patients.
  • In a parallel design, fixed-dose study of 6 weeks duration, the most common adverse drug reactions to Velphoro chewable tablets in hemodialysis patients included discolored feces (12%) and diarrhea (6%).
  • Velphoro can be administered concomitantly with oral calcitriol, ciprofloxacin, digoxin, enalapril, furosemide, HMG-CoA reductase inhibitors, hydrochlorothiazide, losartan, metoprolol, nifedipine, omeprazole, quinidine and warfarin. For oral medications where a reduction of bioavailability would be clinically significant consider separating of the timing of administration. Consider monitoring clinical responses or blood levels of the concomitant medications.

Velphoro is available by prescription only. For additional Safety Information, please see full Prescribing Information.

To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Medical Care Customer Service at 1-800-323-5188 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

This information is intended for use by US healthcare professionals only.

Distributed by:
Fresenius Medical Care North America
Waltham, MA 02451

Fresenius Medical Care Renal Pharmaceuticals

© 2021, 2025 Fresenius Medical Care. All Rights Reserved. Fresenius Medical Care and the triangle logo are trademarks for which Fresenius Medical Care AG holds rights. Velphoro is a trademark of Vifor Fresenius Medical Care Renal Pharma Ltd. All other trademarks are the property of their respective owners.

Do Not Sell or Share My Personal Data • Limit the Use of My Sensitive Personal Information • Consumer Health Data Privacy Policy